Verition Fund Management LLC Biocryst Pharmaceuticals Inc Transaction History

Verition Fund Management LLC

$17.4 Billion
Q3 2024

A detailed history of Verition Fund Management LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Verition Fund Management LLC holds 39,520 shares of BCRX stock, worth $299,166. This represents 0.0% of its overall portfolio holdings.

Number of Shares

39,520

Previous 142,359 72.24%

Holding current value

$299,166

Previous $879,000 65.87%

% of portfolio

0.0%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$6.41 - $8.69 $659,197 - $893,670	-102,839 Reduced 72.24%	39,520 $300,000
Q2 2024 Aug 14, 2024	BUY	$4.13 - $6.79 $587,942 - $966,617	142,359 New	142,359 $879,000
Q4 2023 Feb 14, 2024	SELL	$4.98 - $6.77 $87,000 - $118,271	-17,470 Reduced 35.67%	31,510 $188,000
Q3 2023 Nov 14, 2023	BUY	$6.71 - $7.92 $122,793 - $144,936	18,300 Added 59.65%	48,980 $346,000
Q2 2023 Aug 14, 2023	BUY	$6.96 - $8.81 $58,464 - $74,004	8,400 Added 37.7%	30,680 $215,000
Q1 2023 May 15, 2023	BUY	$7.94 - $11.84 $176,903 - $263,795	22,280 New	22,280 $185,000
Q2 2022 Aug 15, 2022	SELL	$7.89 - $17.88 $122,397 - $277,372	-15,513 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$11.56 - $19.76 $179,330 - $306,536	15,513 New	15,513 $252,000
Q3 2021 Nov 15, 2021	SELL	$14.21 - $17.65 $207,949 - $258,290	-14,634 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$9.5 - $17.24 $139,023 - $252,290	14,634 New	14,634 $231,000
Q4 2020 Feb 16, 2021	SELL	$3.37 - $8.61 $1.83 Million - $4.67 Million	-541,839 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$3.43 - $5.53 $1.86 Million - $3 Million	541,839 New	541,839 $1.86 Million

Others Institutions Holding BCRX

# of Institutions

278

Shares Held

172M

Call Options Held

625K

Put Options Held

739K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verition Fund Management LLC with notifications on news.

Account

Verition Fund Management LLC Biocryst Pharmaceuticals Inc Transaction History